Economic Times07.05.2026BusinessIndia
GeriPower demand to rise by 5-5.5% in FY27: ICRA
HABER
İlgili Haberler
Gelişiyor·14 dk önce
France's watchdog accuses Meta of harming French media over content payments
France's competition watchdog accused Meta of causing "serious and immediate harm" to French media by failing to compensate them for republished content. The watchdog ordered Meta to negotiate payments for "neighbouring rights" with news outlets, citing a 2019 EU directive.
TOI World
Gelişiyor·1 sa önce
IMF Projects India's Economy to Grow 6.4% in FY26-27 Amid Global Slowdown
India's economy is projected to grow 6.4% in FY26-27, driven by strong domestic consumption and services, according to the IMF. Global growth is expected to slow to 3.0% in 2026. The Reserve Bank of India also forecasts robust growth for the country.
Economic Times
Gelişiyor·2 sa önce
India's Luxury Car Market Sees Record Sales in H1 2026, Driven by EVs
Mercedes-Benz and BMW Group reported record sales in India during the first half of 2026, fueled by strong demand for electric vehicles (EVs), premium SUVs, and high-end models. BMW saw a 17% sales increase, with EVs comprising 26% of its total sales.
Times of India
Gelişiyor·5 sa önce
India Cracks Down on Misleading Food Labels, Issues Notices to Major Companies
India's FSSAI has issued show-cause notices to Lotte India, Ferns N Petals, and Kubera Foods for misleading food labels. Products were falsely advertised as '100% Natural' or 'Premium Chocolate' while containing undeclared ingredients or preservatives.
Times of India
Business·6 sa önce
CBDT grants income-tax exemption to NCCL's Core Settlement Guarantee Fund
The Central Board of Direct Taxes (CBDT) has granted income-tax exemption to the Core Settlement Guarantee Fund (CSGF) of National Commodity Clearing Ltd (NCCL) for assessment years 2019-20 to 2026-27, ensuring continued tax benefits under the new Income-Tax Act.
Economic Times
Gelişiyor·6 sa önce
India to Crack Down on Drugmakers Selling Unlisted, Irrational Formulations
India's government plans to penalize drugmakers with unlisted products to stop sales of irrational fixed-dose combinations. Expert committees suggest license cancellation for unapproved formulations, as previous measures failed to ensure compliance.
Economic Times